Workplace Pension Participation and Savings Trends<\/em><\/a>, which is available on GOV.UK. This publication includes aggregated data from large private pension providers in which the proportion of new member enrolments to have opted-out of workplace pension saving stood at 11.79% in July 2023. Over the period from January 2020 to July 2023, these opt-out rates have fluctuated between a low of 7.03% and a high of 12.23%. From the same aggregated private pension provider data, the proportion of pension scheme members making an active decision to cease saving was 0.50% in July 2023.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3926", "label" : {"_value" : "Biography information for Paul Maynard"}
}
, "answeringMemberConstituency" : {"_value" : "Blackpool North and Cleveleys"}
, "answeringMemberPrinted" : {"_value" : "Paul Maynard"}
, "dateOfAnswer" : {"_value" : "2024-04-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-16T10:02:23.057Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "29"}
, "answeringDeptShortName" : {"_value" : "Work and Pensions"}
, "answeringDeptSortName" : {"_value" : "Work and Pensions"}
, "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Workplace Pensions"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Work and Pensions, how many people opted out of auto-enrolment workplace pension schemes in each of the last ten years for which figures are available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/178", "label" : {"_value" : "Biography information for John McDonnell"}
}
, "tablingMemberConstituency" : {"_value" : "Hayes and Harlington"}
, "tablingMemberPrinted" : [{"_value" : "John McDonnell"}
], "uin" : "20845"}
, {"_about" : "http://data.parliament.uk/resources/1700034", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1700034/answer", "answerText" : {"_value" : "The National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. Decisions on the availability of medicines in Scotland are a matter for the devolved administration.<\/p>
The NICE published guidance in 2021 and 2023 recommending Enhertu, also known as trastuzumab deruxtecan, for the treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS patients in England in line with the NICE\u2019s recommendations.<\/p>
The NICE is currently evaluating Enhertu for the treatment of metastatic HER2-low breast cancer, and has not yet published final guidance. Stakeholders have had an opportunity to appeal against the NICE\u2019s draft recommendations, and the NICE will consider any appeals through the established process and publish final guidance in due course.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-16T15:01:22.04Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Trastuzumab Deruxtecan"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the adequacy of the reasons the (a) National Institute for Health and Care Excellence has been unable and (b) Scottish Medicines Consortium has been able to recommend Enhertu for use on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"}
}
, "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"}
, "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"}
], "uin" : "20959"}
, {"_about" : "http://data.parliament.uk/resources/1700068", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1700068/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether Enhertu can be recommended for routine NHS funding, based on an assessment of the costs and benefits. The NICE was unfortunately unable to recommend Enhertu as a clinically and cost-effective use of NHS resources in its final draft guidance published on 5 March 2024. Stakeholders have had an opportunity to appeal against the NICE\u2019s draft recommendations, and the NICE will consider any appeals through the established process, and will publish final guidance in due course.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-16T15:03:45.557Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Trastuzumab Deruxtecan"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether NICE is taking steps to make Enhertu available to the National Health Service to treat incurable HER2-low secondary breast cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/350", "label" : {"_value" : "Biography information for Sir John Hayes"}
}
, "tablingMemberConstituency" : {"_value" : "South Holland and The Deepings"}
, "tablingMemberPrinted" : [{"_value" : "Sir John Hayes"}
], "uin" : "20865"}
, {"_about" : "http://data.parliament.uk/resources/1700249", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1700249/answer", "answerText" : {"_value" : "
The Government commissioned the Patient Safety Commissioner (PSC) to produce a report on redress for those affected by sodium valproate and pelvic mesh. We are grateful to the PSC and her team for completing this report, and our sympathies remain with those affected by sodium valproate and pelvic mesh. The Government is now carefully considering the PSC\u2019s recommendations, and will respond substantively in due course.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-04-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-16T13:36:40.457Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Sodium Valproate: Compensation"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what her planned timetable is for publishing a response to the Hughes Report on compensation for patients damaged by sodium valproate, published 7 February 2024.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4418", "label" : {"_value" : "Biography information for Justin Madders"}
}
, "tablingMemberConstituency" : {"_value" : "Ellesmere Port and Neston"}
, "tablingMemberPrinted" : [{"_value" : "Justin Madders"}
], "uin" : "21105"}
, {"_about" : "http://data.parliament.uk/resources/1700288", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1700288/answer", "answerText" : {"_value" : "
The Child Maintenance Service (CMS) has a range of enforcement powers at its disposal to ensure parents meet their financial obligations to their children.<\/p>
These include deductions directly from earnings and bank accounts, using Enforcement Agents (previously known as bailiffs) to take control of goods, forcing the sale of property, removal of driving licence or UK passport or even commitment to prison.<\/p>
The Child Support (Enforcement) Act received Royal Assent in 2023. This creates a primary power to replace court-based liability orders with administrative orders, which should significantly speed up this key enforcement process.<\/p>
<\/p>
We have concluded a public consultation to support regulations to implement administrative liability orders. The Government published their response on 12 February 2024.<\/p>
<\/p>
Secondary legislation is now being developed, which, once implemented, will reduce the process from 22 weeks to as low as 6 weeks.\u202fThis will be brought forward as soon as possible.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3926", "label" : {"_value" : "Biography information for Paul Maynard"}
}
, "answeringMemberConstituency" : {"_value" : "Blackpool North and Cleveleys"}
, "answeringMemberPrinted" : {"_value" : "Paul Maynard"}
, "dateOfAnswer" : {"_value" : "2024-04-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-16T15:35:55.103Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "29"}
, "answeringDeptShortName" : {"_value" : "Work and Pensions"}
, "answeringDeptSortName" : {"_value" : "Work and Pensions"}
, "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Children: Maintenance"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Work and Pensions, what steps his Department is taking to ensure that people pay the full child maintenance costs for which they are liable.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4139", "label" : {"_value" : "Biography information for Ian Lavery"}
}
, "tablingMemberConstituency" : {"_value" : "Wansbeck"}
, "tablingMemberPrinted" : [{"_value" : "Ian Lavery"}
], "uin" : "21039"}
, {"_about" : "http://data.parliament.uk/resources/1700334", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1700334/answer", "answerText" : {"_value" : "
The Breast Screening Risk Adaptive Imaging for Density trial is looking into the use of supplementary imaging techniques for women, within the standard breast screening programme, who are found to have radiographically dense breast tissue. The UK National Screening Committee, which advises ministers and the National Health Service in all four countries in the United Kingdom, will review this evidence when it becomes available.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-16T10:56:31.723Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Breast Cancer: Screening"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether her Department has made a recent assessment of the potential merits of using breast density assessment software at women's first breast cancer screening appointments; and if she will make an assessment of the potential impact of that technology on women's awareness of their personal risk of developing breast cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4509", "label" : {"_value" : "Biography information for Craig Tracey"}
}
, "tablingMemberConstituency" : {"_value" : "North Warwickshire"}
, "tablingMemberPrinted" : [{"_value" : "Craig Tracey"}
], "uin" : "21156"}
, {"_about" : "http://data.parliament.uk/resources/1700510", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1700510/answer", "answerText" : {"_value" : "
To make a medicinal product available for sale in a pharmacy without a prescription, the product must be reclassified to pharmacy only status, also known as [P] medicines, by the Medicines and Healthcare products Regulatory Agency (MHRA).<\/p>
This process is triggered by an application submitted to the MHRA by a company which holds a licence for the particular product. The MHRA will consider all submitted applications, with a decision to reclassify a medicine reached following a robust evaluation of the relevant data, including evidence of the safe use and supply of the product without a prescription. The company must also demonstrate in their application that the criteria specified in relevant legislation, such as the Human Medicines Regulations 2012, have been met.<\/p>
In accordance with the Human Medicines Regulations 2012, regulation 62(3), Prescription-Only Medicine status will apply where: a direct or indirect danger exists to human health, even when used correctly, if used without medical supervision; there is frequently incorrect use, which could lead to direct or indirect danger to human health; further investigation of the activity or side-effects is required; or the product is normally prescribed for parenteral administration, via injection.<\/p>
Currently, United Kingdom law specifies that all products administered by injection must be subject to a prescription. The MHRA is therefore unable to reclassify the status of injections, including Vitamin B12, to [P] medicines, as this would not be consistent with the legislation.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-16T11:03:29.56Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will make it her policy to allow pharmacies to sell vitamin B12 injections.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4839", "label" : {"_value" : "Biography information for Jane Hunt"}
}
, "tablingMemberConstituency" : {"_value" : "Loughborough"}
, "tablingMemberPrinted" : [{"_value" : "Jane Hunt"}
], "uin" : "21397"}
, {"_about" : "http://data.parliament.uk/resources/1700548", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1700548/answer", "answerText" : {"_value" : "
To deliver the NHS Long Term Plan\u2019s mental health commitments and help reduce waiting times in the Wellingborough constituency and nationwide, our aim has been to grow the mental health workforce nationally by an additional 27,000 professionals by March 2024.<\/p>
<\/p>
We are making positive progress, delivering three quarters of this, or approximately 20,800 new professionals, by December 2023, with further growth expected to have been achieved once the full year figures for 2023/24 are available. This growth is in addition to the commitment to grow the National Health Service\u2019s mental health workforce by 19,000 between 2016/17 and 2020/21, as set out in Stepping Forward to 2020/21: the mental health workforce plan for England, which was achieved in September 2021.<\/p>
<\/p>
At a national level, we are committed to attracting, training, and recruiting the mental health workforce of the future, as well as retaining and developing our current workforce. The NHS Long Term Workforce Plan\u2019s modelling projections set out a need to grow the overall mental health and learning disability workforce the fastest of all care settings, at 4.4% per year up to 2036/37, to help improve access to services and quality of care.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-04-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-16T10:53:27.36Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mental Health Services: Wellingborough"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking to support the recruitment and retention of mental health specialists in Wellingborough constituency.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/5011", "label" : {"_value" : "Biography information for Gen Kitchen"}
}
, "tablingMemberConstituency" : {"_value" : "Wellingborough"}
, "tablingMemberPrinted" : [{"_value" : "Gen Kitchen"}
], "uin" : "21433"}
, {"_about" : "http://data.parliament.uk/resources/1700570", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1700570/answer", "answerText" : {"_value" : "
The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is currently funding research to address measurement bias in the assessment of the presentation of autism in women, and to develop a new psychometric tool assessing the female-dominant phenotype of autism. The NIHR previously funded a study to improve the accuracy and efficiency of autism assessment for adults which, while not specific to women, will be relevant to their experiences of receiving a diagnosis. The NIHR has also funded research into topics that impact autistic individuals differently, for example how to adapt suicide safety plans to address self-harm, suicidal ideation, and suicide behaviours in autistic adults.<\/p>
The NIHR welcomes funding applications for research into any aspect of human health, including the impact of autism and attention deficit hyperactivity disorder on women. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-16T11:36:36.717Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Neurodiversity: Women"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will commission research into the impact of (a) autism and (b) ADHD on women.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4620", "label" : {"_value" : "Biography information for Ellie Reeves"}
}
, "tablingMemberConstituency" : {"_value" : "Lewisham West and Penge"}
, "tablingMemberPrinted" : [{"_value" : "Ellie Reeves"}
], "uin" : "21455"}
, {"_about" : "http://data.parliament.uk/resources/1700571", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1700571/answer", "answerText" : {"_value" : "
The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is not currently funding any specific research into the impact of hormonal changes on neurodiverse women, but welcomes funding applications for research into any aspect of human health. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money, and scientific quality.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-04-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-16T11:14:48.62Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Neurodiversity: Women"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will commission research into the impact of hormonal changes on neurodiverse women throughout their lives.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4620", "label" : {"_value" : "Biography information for Ellie Reeves"}
}
, "tablingMemberConstituency" : {"_value" : "Lewisham West and Penge"}
, "tablingMemberPrinted" : [{"_value" : "Ellie Reeves"}
], "uin" : "21456"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&_properties=answer.isMinisterialCorrection,tablingMember.label,answeringDeptSortName,answer.questionFirstAnswered", "page" : 0, "startIndex" : 1, "totalResults" : 510690, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}